First Time Loading...
T

TOT BIOPHARM International Co Ltd
HKEX:1875

Watchlist Manager
TOT BIOPHARM International Co Ltd
HKEX:1875
Watchlist
Price: 2.2 HKD Market Closed
Updated: Jun 6, 2024

TOT BIOPHARM International Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

TOT BIOPHARM International Co Ltd
Cost of Revenue Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
T
TOT BIOPHARM International Co Ltd
HKEX:1875
Cost of Revenue
-¥206.6m
CAGR 3-Years
-210%
CAGR 5-Years
-103%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cost of Revenue
-¥2.7B
CAGR 3-Years
-77%
CAGR 5-Years
-70%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cost of Revenue
-¥1.1B
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cost of Revenue
-¥992.7m
CAGR 3-Years
-28%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cost of Revenue
-¥39.6B
CAGR 3-Years
-58%
CAGR 5-Years
-63%
CAGR 10-Years
-63%
Imeik Technology Development Co Ltd
SZSE:300896
Cost of Revenue
-¥99.9m
CAGR 3-Years
-34%
CAGR 5-Years
-27%
CAGR 10-Years
N/A

See Also

What is TOT BIOPHARM International Co Ltd's Cost of Revenue?
Cost of Revenue
-206.6m CNY

Based on the financial report for Dec 31, 2023, TOT BIOPHARM International Co Ltd's Cost of Revenue amounts to -206.6m CNY.

What is TOT BIOPHARM International Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-103%

Over the last year, the Cost of Revenue growth was -189%. The average annual Cost of Revenue growth rates for TOT BIOPHARM International Co Ltd have been -210% over the past three years , -103% over the past five years .